Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Sitaru, C; Thiel, J.
The need for markers and predictors of Rituximab treatment resistance.
Exp Dermatol. 2014; 23(4):236-7
Doi: 10.1111/exd.12331
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Thiel Jens
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- CD20-specific antibodies show remarkable therapeutic efficacy in B-cell malignancy and autoimmune diseases, but due to the occurrence of a significant treatment resistance, a critical, unmet need for improving B-cell-depleting approaches remains. A CD20 transcript variant (D393-CD20) appears to be associated with Rituximab treatment resistance in malignant B cells, but is lacking in patients with autoimmune dermatoses as shown by Gamonet et al. While CD20-specific factors certainly play a major role in the pathogenesis of Rituximab treatment resistance, the D393-CD2 transcript may greatly facilitate the development of clinical markers for monitoring the therapy in B-cell malignancies and (auto)antibody-mediated diseases. Its association with systemic autoimmune diseases should be therefore explored in further studies.
- Find related publications in this database (using NLM MeSH Indexing)
- Alternative Splicing - administration & dosage
- Antibodies, Monoclonal, Murine-Derived - therapeutic use
- Antigens, CD20 - metabolism
- Autoimmune Diseases - drug therapy
- Biomarkers - metabolism
- Drug Resistance, Neoplasm - administration & dosage
- Humans - administration & dosage
- Immunologic Factors - therapeutic use
- Rituximab - administration & dosage
- Skin Diseases - drug therapy
- Find related publications in this database (Keywords)
- B cell lymphoma
- connective tissue diseases
- pemphigoid
- pemphigus
- vasculitides